These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 4830223)

  • 1. Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia.
    Charlesworth JA; Williams DG; Sherington E; Lachmann PJ; Peters DK
    J Clin Invest; 1974 Jun; 53(6):1578-87. PubMed ID: 4830223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation and composition of the C3 activating enzyme complex of the properdin system. Sequential assembly of its components on solid-phase trypsin-agarose.
    Vogt W; Schmidt G; Dieminger L; Lynen R
    Z Immunitatsforsch Exp Klin Immunol; 1975 Jul; 149(5):440-55. PubMed ID: 126576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation.
    Sissons JG; Liebowitch J; Amos N; Peters DK
    J Clin Invest; 1977 Apr; 59(4):704-15. PubMed ID: 845257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proceedings: Metabolism of C3 and glycine-rich beta glycoprotein (GBG) in hypocomplementaemia.
    Peters DK; Charlesworth JA; Williams DG; Sissons JG; Lachmann PJ
    Clin Sci Mol Med; 1974 Feb; 46(2):17P. PubMed ID: 4817262
    [No Abstract]   [Full Text] [Related]  

  • 5. Inactivator of the third component of complement as an inhibitor in the properdin pathway.
    Alper CA; Rosen FS; Lachmann PJ
    Proc Natl Acad Sci U S A; 1972 Oct; 69(10):2910-3. PubMed ID: 4507613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship of glycine-rich -glycoprotein to factor B in the properdin system and to the cobra factor-binding protein of huan serum.
    Alper CA; Goodkofsky I; Lepow IH
    J Exp Med; 1973 Feb; 137(2):424-37. PubMed ID: 4734403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection.
    Alper CA; Abramson N; Johnston RB; Jandl JH; Rosen FS
    J Clin Invest; 1970 Nov; 49(11):1975-85. PubMed ID: 4097977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hereditary deficiency of the third component of complement in a child with fever, skin rash, and arthralgias: response to transfusion of whole blood.
    Osofsky SG; Thompson BH; Lint TF; Gewurz H
    J Pediatr; 1977 Feb; 90(2):180-6. PubMed ID: 318684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.
    Ziegler JB; Alper CA; Rosen RS; Lachmann PJ; Sherington L
    J Clin Invest; 1975 Mar; 55(3):668-72. PubMed ID: 1117072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypercatabolism of the third component of complement in patients with primary biliary cirrhosis.
    Potter BJ; Elias E; Jones EA
    J Lab Clin Med; 1976 Sep; 88(3):427-39. PubMed ID: 956695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C3 metabolism in a patient with deficiency of the second component of complement (C2) and discoid lupus erythematosus.
    Wild JH; Zvaifler NJ; Müller-Eberhard HJ; Wilson CB
    Clin Exp Immunol; 1976 May; 24(2):238-48. PubMed ID: 1084239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic behavior of C3 in normal, C4-deficient (C4D) and cortisone-treated guinea pigs.
    Atkinson JP; Shin H; Frank MM
    J Immunol; 1974 Oct; 113(4):1085-92. PubMed ID: 4414646
    [No Abstract]   [Full Text] [Related]  

  • 13. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
    Vogt W; Schmidt G; Lynen R; Dieminger L
    J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
    Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
    J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased susceptibility to infection in a patient with type II essential hypercatabolism of C3.
    Alper CA; Bloch KJ; Rosen FS
    N Engl J Med; 1973 Mar; 288(12):601-6. PubMed ID: 4686987
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of activation of the properdin system. Studies on properdin electrophoretic mobility in agarose activation of the alternative pathway.
    Adam C; Williams DG; Peters DK
    Clin Exp Immunol; 1975 Nov; 22(2):240-8. PubMed ID: 813932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism of human beta 1H: studies in man and experimental animals.
    Charlesworth JA; Scott DM; Pussell BA; Peters DK
    Clin Exp Immunol; 1979 Dec; 38(3):397-404. PubMed ID: 535181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement and mesangiocapillary glomerulonephritis role of complement deficiency in the pathogenesis of nephritis.
    Peters DK; Williams DG
    Nephron; 1974; 13(3):188-97. PubMed ID: 4278792
    [No Abstract]   [Full Text] [Related]  

  • 20. Alternative pathway complement activation in rheumatoid arthritis.
    El-Ghobarey A; Whaley K
    J Rheumatol; 1980; 7(4):453-60. PubMed ID: 6158571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.